ARTICLE | Company News
Lipid Therapeutics, Dr. Falk Pharma deal
March 12, 2012 7:00 AM UTC
Dr. Falk exercised an option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics. Lipid Therapeutics will receive an undisclosed upfront payment and will be eligible for milestones and royalties. Details were not disclosed. According to Dr. Falk, the decision to exercise the option was based on the "positive outcome" of a Phase IIb trial. Last June, Lipid said LT-02 met the trial's primary endpoint of reducing Simple Clinical Colitis Activity Index (SCCAI) scores from baseline to week 12 vs. placebo (see BioCentury, June 27, 2011). ...